182 related articles for article (PubMed ID: 19825950)
1. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
Cohen RB; Jones SF; Aggarwal C; von Mehren M; Cheng J; Spigel DR; Greco FA; Mariani M; Rocchetti M; Ceruti R; Comis S; Laffranchi B; Moll J; Burris HA
Clin Cancer Res; 2009 Nov; 15(21):6694-701. PubMed ID: 19825950
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
Steeghs N; Eskens FA; Gelderblom H; Verweij J; Nortier JW; Ouwerkerk J; van Noort C; Mariani M; Spinelli R; Carpinelli P; Laffranchi B; de Jonge MJ
J Clin Oncol; 2009 Oct; 27(30):5094-101. PubMed ID: 19770380
[TBL] [Abstract][Full Text] [Related]
3. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Steeghs N; Mathijssen RH; Wessels JA; de Graan AJ; van der Straaten T; Mariani M; Laffranchi B; Comis S; de Jonge MJ; Gelderblom H; Guchelaar HJ
Invest New Drugs; 2011 Oct; 29(5):953-62. PubMed ID: 20182906
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
Dees EC; Rowinsky EK; Noe DA; O'Reilly S; Adjei AA; Elza-Brown K; Donehower RC
Invest New Drugs; 2003 Feb; 21(1):75-84. PubMed ID: 12795532
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.
Meulenbeld HJ; Bleuse JP; Vinci EM; Raymond E; Vitali G; Santoro A; Dogliotti L; Berardi R; Cappuzzo F; Tagawa ST; Sternberg CN; Jannuzzo MG; Mariani M; Petroccione A; de Wit R
BJU Int; 2013 Jan; 111(1):44-52. PubMed ID: 22928785
[TBL] [Abstract][Full Text] [Related]
8. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI
Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Masters GA; Brockstein BE; Mani S; Ratain MJ
Med Oncol; 2003; 20(1):7-12. PubMed ID: 12665678
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
12. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia.
Haim N; Shulman K; Goldberg H; Tsalic M
Med Oncol; 2005; 22(3):229-32. PubMed ID: 16110133
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial.
Sandler A; Fox S; Meyers T; Christou A; Weber G; Gonin R; Loehrer PJ; Einhorn LH; Dreicer R
Am J Clin Oncol; 1998 Apr; 21(2):180-4. PubMed ID: 9537208
[TBL] [Abstract][Full Text] [Related]
14. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
[TBL] [Abstract][Full Text] [Related]
16. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
Dees EC; Infante JR; Cohen RB; O'Neil BH; Jones S; von Mehren M; Danaee H; Lee Y; Ecsedy J; Manfredi M; Galvin K; Stringer B; Liu H; Eton O; Fingert H; Burris H
Cancer Chemother Pharmacol; 2011 Apr; 67(4):945-54. PubMed ID: 20607239
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
